Spexis

Spexis AG is a publicly traded biopharma focused on discovering and developing novel macrocyclic therapeutics for rare diseases and cancer. Its strategy is built upon two proprietary technology platforms: a Macrocycle Platform for undruggable targets and an OMPTA Platform for antibiotic-resistant Gram-negative infections. The company's most advanced program, ColiFin®, is an approved inhaled therapy for cystic fibrosis, positioning Spexis with a late-stage asset while advancing earlier clinical and pre-clinical candidates. Spexis is actively seeking development and commercialization partners to maximize the value of its pipeline and platforms.

Spexis leverages two proprietary platforms: a Macrocycle Platform for targeting undruggable protein-protein interactions, and an OMPTA Platform for developing novel antibiotics against multidrug-resistant Gram-negative bacteria.

In cystic fibrosis, Spexis competes with established players like Vertex Pharmaceuticals. Its OMPTA antibiotics face competition from other novel Gram-negative antibiotic developers such as Venatorx and Shionogi. The macrocycle platform competes with other modalities targeting protein-protein interactions, including protein degraders and molecular glues from companies like Arvinas and Kymera.